Toregem BioPharma raises $5.3M to bring tooth-regrowing drug to Phase II trials
What's the deal? Kyoto-based Toregem BioPharma has raised $5.3M (US$6.54M) in a Pre-Series C round to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The funding brings the company's total backing — including grants, subsidies, and equity — past $29M.
TRG035 works by blocking a protein that suppresses tooth growth, aiming to stimulate dormant tooth buds. If successful, it could become the world's first tooth-regeneration therapy.
The round included existing investor JIC Venture Growth Investments and new backers such as Osaka University Venture Capital, BI Holdings, SHOFU, SIIF Impact Capital, and Chushin Venture Capital.
Why now? The raise follows Toregem's Phase I trial, launched at Kyoto University Hospital in October 2024. That study enrolled 30 healthy adult men aged 30 to 64, each missing at least one molar, to evaluate safety. With that data in hand, the company is now preparing to move into efficacy-focused Phase II trials in Japan — and laying the groundwork for future clinical development in the US.
What could go wrong? Tooth regeneration remains uncharted territory in medicine. Phase II trials must demonstrate not just safety but actual therapeutic effect — a far higher bar. Regulatory pathways in both Japan and the US could prove long and uncertain, and there is no precedent for this class of drug to guide expectations.
Initial trials also focus on a narrow patient group: children with congenital tooth agenesis, a condition where teeth never develop. Expanding to broader applications — such as tooth loss from ageing or injury — would require substantially more clinical evidence.
The signal: Toregem sits at the intersection of two growing trends: regenerative medicine and the commercialisation of research from Japan's government-backed innovation ecosystem. The company has drawn significant public support alongside private capital, a model increasingly common in Japanese biotech.
If TRG035 works, it would open a massive market. Hundreds of millions of people worldwide deal with tooth loss, and current solutions — implants, dentures, bridges — are expensive, imperfect, and often require ongoing maintenance. A drug that regrows teeth would be a category-defining breakthrough.
For now, though, the science has to prove itself in the clinic.
Source: economictimes.indiatimes.com
